

Do Comorbidities Play a Role in Hand Osteoarthritis Disease Burden? Data from the Hand Osteoarthritis in Secondary Care Cohort

Wendy Damman, Rani Liu, Féline P.B. Kroon, Monique Reijnerse, Tom W.J. Huizinga, Frits R. Rosendaal, and Margreet Kloppenburg

ABSTRACT. *Objective.* Because the association and its clinical relevance between comorbidities and primary hand osteoarthritis (OA) disease burden is unclear, we studied this in patients with hand OA from our Hand Osteoarthritis in Secondary care (HOSTAS) cohort.

Methods. Cross-sectional data from the HOSTAS study were used, including consecutive patients with primary hand OA. Nineteen comorbidities were assessed: 18 self-reported (modified Charlson index and osteoporosis) and obesity (body mass index ≥ 30 kg/m²). Mean differences were estimated between patients with versus without comorbidities, adjusted for age and sex: for general disease burden [health-related quality of life (HRQOL), Medical Outcomes Study Short Form-36 physical component scale (0–100)] and disease-specific burden [self-reported hand function (0–36), pain (0–20; Australian/Canadian Hand OA Index), and tender joint count (TJC, 0–30)]. Differences above a minimal clinically important improvement/difference were considered clinically relevant.

Results. The study included 538 patients (mean age 61 yrs, 86% women, 88% fulfilled American College of Rheumatology classification criteria). Mean (SD) HRQOL, function, pain, and TJC were 44.7 (8), 15.6 (9), 9.3 (4), and 4.8 (5), respectively. Any comorbidity was present in 54% (287/531) of patients and this was unfavorable [adjusted mean difference presence/absence any comorbidity (95% CI): HRQOL -4.4 (-5.8 to -3.0), function 1.9 (0.4–3.3), pain 1.4 (0.6–2.1), TJC 1.3 (0.4–2.2)]. Number of comorbidities and both musculoskeletal (e.g., connective tissue disease) and nonmusculoskeletal comorbidities (e.g., pulmonary and cardiovascular disease) were associated with disease burden. Associations with HRQOL and function were clinically relevant.

Conclusion. Comorbidities showed clinically relevant associations with disease burden. Therefore, the role of comorbidities in hand OA should be considered when interpreting disease outcomes and in patient management. (First Release September 15 2017; J Rheumatol 2017;44:1659–66; doi:10.3899/jrheum.170208)

Key Indexing Terms:

HAND OSTEOARTHRITIS
DISABILITY

COMORBIDITY
HAND PAIN

PATIENT-REPORTED OUTCOMES
QUALITY OF LIFE

Hand pain and impaired function are major problems in patients with hand osteoarthritis (OA)¹. A wide range of factors have been shown to be associated with these complaints. These are not limited to joint-specific factors

such as bony enlargements, inflammation, and radiographic damage, but also include psychosocial factors such as coping and illness perceptions^{2,3,4,5}. Another factor that could play a role is comorbidity. Comorbidity (i.e., any additional disease co-occurring with a primary disease) or multimorbidity (i.e., 2 or more co-occurring medical conditions in 1 patient) is associated with disease outcomes⁶ and has a clinical role in patient management, as was recently recognized by a European League Against Rheumatism initiative on comorbidities in chronic inflammatory rheumatic diseases⁷. Patients with OA could also benefit when comorbidities such as cardiovascular (CV) disease and osteoporosis are taken into consideration⁷.

Multimorbidity, including depression^{8,9}, has been investigated in many population-based studies, showing associations between presence of multimorbidity and increased disease burden^{8,10,11,12}. In these studies, disease burden was either defined as general burden [health-related quality of life

From the departments of Rheumatology, Radiology, and Clinical Epidemiology, Leiden University Medical Center (LUMC), Leiden, the Netherlands.

Funding from the Dutch Arthritis Foundation (Reumafonds): LLP-24 for the HOSTAS cohort and appointment of the first author.

W. Damman, MD, Department of Rheumatology, LUMC; R. Liu, MD, Department of Rheumatology, LUMC; F.P. Kroon, MD, Department of Rheumatology, LUMC; M. Reijnerse, MD, PhD, Department of Radiology, LUMC; T.W. Huizinga, MD, PhD, Department of Rheumatology, LUMC; F.R. Rosendaal, MD, PhD, Department of Clinical Epidemiology, LUMC; M. Kloppenburg, MD, PhD, Department of Rheumatology, and Department of Clinical Epidemiology, LUMC.

Address correspondence to Dr. W. Damman, Department of Rheumatology, Leiden University Medical Centre, CI-R, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail: w.damman@lumc.nl

Accepted for publication July 6, 2017.

(HRQOL)] or as disease-specific burden (e.g., functional ability⁶). Because many patients with hand OA are elderly, comorbidity in these patients is likely to occur^{13,14,15,16}. Despite this situation, the relationship between comorbidity and disease-specific burden in hand OA, i.e., impaired hand function and hand pain, is scarcely studied.

In patients with OA at other sites, i.e., knee and hip OA, it is reported that musculoskeletal comorbidities such as back disorders and osteoporosis, but also nonmusculoskeletal comorbidities such as diabetes mellitus, chronic pulmonary disease, and depression, are associated with decreased HRQOL and increased disability and joint pain^{17,18,19,20,21,22}. Although many patients with OA who consult a rheumatologist may have hand OA^{1,23}, previous research only studied associations between hand OA and a few comorbidities, including generalized OA²³, depression, upper extremity comorbidity²⁴, and diabetes²⁵. The clinical relevance of the role of these comorbidities was not studied.

Insight into the role of comorbidities in hand OA disease burden is not only important from a clinical perspective, but also from a methodological one. When comorbidities act as effect modifiers of disease outcomes, they can be considered as contextual factor(s). These factors, influencing outcome interpretation, should be taken into account in clinical trials and observational studies^{7,26,27}.

Therefore, we aimed to study the association between comorbidities and general HRQOL, as well as disease-specific burden (hand function and hand pain) in patients with hand OA. First, we will describe the clinical characteristics and prevalent comorbidities in a large cohort of primary hand OA patients from our outpatient clinic. Second, we will estimate the cross-sectional association between presence and number of comorbidities or specific types of comorbidities and hand OA disease burden. Third, we will evaluate the clinical relevance of the results.

MATERIALS AND METHODS

Study population and recruitment. Baseline data from the Hand OSTeoArthritis in Secondary care (HOSTAS) study were used, an observational cohort aiming at investigating determinants of outcome and utility of clinimetric instruments in primary hand OA. Consecutive patients from the Leiden University Medical Center (LUMC) outpatient clinic were included between June 2009 and October 2015. Primary hand OA was diagnosed according to the clinical judgment of the treating rheumatologist. The LUMC serves both as a secondary and tertiary referral center for rheumatic diseases, enabling inclusion of patients with primary hand OA in all disease stages. Exclusion criteria included any pathological condition that could explain the patient's symptoms (e.g., tendinitis, carpal tunnel syndrome, strain, fibromyalgia, arthritis due to other rheumatic diseases), secondary OA [including inflammatory joint diseases such as rheumatoid arthritis (RA), psoriatic arthritis, spondyloarthropathies, and current sarcoidosis; bone diseases such as osteitis deformans and osteochondritis, intraarticular fractures; metabolic diseases associated with joint diseases such as hemochromatosis, Wilson's disease, and ochronosis; endocrine diseases such as acromegaly, major congenital or developmental diseases, bone dysplasias; and major local factors such as hypermobility and severe gout], and language barriers or psychological limitations that precluded giving informed consent or completing study visits. Written informed consent was obtained from all

participants. The study was approved by the LUMC medical ethical committee (CCMO reference NL26201.058.08).

Patient characteristics and patient-reported outcomes. Demographic data and patient characteristics were collected using standardized questionnaires (Table 1). Education level was used as a proxy for socioeconomic status and divided into 3 groups: low (no education, primary school only, lower vocational education), middle (lower general secondary, secondary vocational education), and high (all higher education).

To study general disease burden, HRQOL was measured with the Dutch Research and Development (RAND) translation (version 1) of the Medical Outcomes Study Short Form-36 (SF-36)²⁸. Because no norm values are available for the RAND-36 translation, we used the scoring algorithm and age- and sex-specific Dutch population-based norm scores from the Dutch SF-36 translation to apply norm-based scoring²⁹. The 2 translations are

Table 1. Baseline characteristics of a hand osteoarthritis (OA) population (n = 538) in secondary care — the HOSTAS cohort.

Characteristics	Values
Age, yrs, mean (SD)	61.0 (8.6)
Sex, women, n (%)	463 (86)
BMI, mean (SD)	27.1 (4.8)
Marital status, married, n (%)	395 (75)
Employment, n (%)	
Working	215 (41)
Pension	161 (31)
Sickness leave/work disabled	67 (13)
Education level, n (%)	
Low	141 (27)
Middle	204 (39)
High	179 (34)
General and disease-specific burden	
Self-reported health-related quality of life, mean (SD)	
PCS	44.7 (8.2)
MCS	51.7 (8.7)
Self-reported function 0–36, mean (SD)	15.6 (8.5)
Self-reported pain 0–20, mean (SD)	9.3 (4.3)
Hand-specific disease characteristics	
Symptom duration, yrs, mean (SD)	8.7 (9.0)
Dominance hand, right, n (%)	419 (80)
Fulfilling ACR criteria for hand OA, n (%)	476 (88)
Physical examination, median (range)	
Tender joint count 0–30	3 (0–30)
Bony swelling joint count 0–30	11 (0–24)
Soft swollen joint count 0–30	0 (0–17)
Deformity joint count 0–22	3 (0–16)
Joints with limited ROM 0–22	4 (0–22)
Radiographic scoring, median (range)	
KL summated score 0–120	17 (0–89)
KL ≥ 2 joint count 0–30	4 (0–29)
Osteophytes summated score 0–56	9 (0–47)
JSN summed score 0–56	7 (0–45)
Erosive disease, n (%) of patients	154 (29)
Pain medication, yes, n (%)	351 (67)
Acetaminophen	257 (49)
NSAID	168 (32)
Nutraceuticals, yes, n (%)	162 (31)

HOSTAS: Hand OSTeoArthritis in Secondary care; BMI: body mass index; PCS: physical component score; MCS: mental component summary; ACR: American College of Rheumatology; ROM: range of motion; KL: Kellgren-Lawrence (osteo)arthritis grading scale; JSN: joint space narrowing; NSAID: nonsteroidal antiinflammatory drugs.

different only in wording, and when using the right scoring algorithm, they are practically interchangeable. We calculated 2 summary component scores: physical health (PCS; further used to assess HRQOL) and mental health (MCS) and standardized scores: scale 0–100, mean 50, SD 10. Lower scores represent worse health. A minimal clinically important difference (MCID) of 2 was reported³⁰. We compared mean differences to this value to evaluate clinical relevance.

To study the disease-specific burden, self-reported hand function (0–36) and hand pain (0–20) were assessed by the Australian/Canadian hand OA index (AUSCAN; Likert scale). Higher scores indicate worse health³¹. Clinical relevance was analyzed in 2 ways. First, mean differences were compared with a minimal clinically important improvement (MCII); MCII (95% CI) function 1.4 (0.1–2.2) and pain 1.6 (1.0–2.0) are on a scale 0–36 and 0–20, respectively³².

Second, we used age- and sex-specific cutoff values based on reference values of the 95th percentiles for ages 45, 50, 55, 60, and 65 years of the AUSCAN distribution in the general population³³. This means that when a patient has a score above this 95th percentile value, 95% of the general population has a lower score. We considered it clinically relevant when a patient has a score that is in the highest 5% of the population. Only reference values for the ages 45, 50, 55, 60, and 65 were available. Therefore, we extrapolated the cutoff values to 5 age categories: < 47.5 years (corresponding to values for age 45), ≥ 47.5 to < 52.5 (age 50), ≥ 52.5 to < 57.5 (age 55), ≥ 57.5 to < 62.5 (age 60), and ≥ 62.5 (age 65), respectively.

Clinical assessment. Physical examination was performed by trained research nurses, assessing the distal interphalangeal (DIP), proximal interphalangeal (PIP), interphalangeal (IP), metacarpophalangeal (MCP), and first carpometacarpal joints of both hands (30 per patient) for tenderness upon palpation, bony and soft swelling, deformity, and limited range of motion (last 2 characteristics not in MCP). To study disease-specific burden, tender joints upon palpation were summated into tender joint count (TJC). Crepitus, bony tenderness, bony enlargement, and palpable warmth of the knee and internal rotation of the hip were also examined. Body mass index (BMI; kg/m²) was calculated using measured weight and height.

OA definition. The rheumatologist's diagnosis of hand OA was used as an inclusion criterion in HOSTAS. Additionally, the number of patients fulfilling the American College of Rheumatology (ACR) criteria for hand OA was determined³⁴. For patients not fulfilling these criteria, we ascertained whether they definitely had hand OA (radiographic and/or structural features). Knee or hip OA was assessed using the ACR criteria based on history and physical examination^{35,36}. Also, joints with a prosthesis, arthroplasty, or arthrodesis with indication "OA, worn-out or pain" were regarded as having endstage OA. For the hands, endstage OA (i.e., arthrodesis/arthroplasty in a hand joint), meant that we considered the ACR criterion "hand pain, aching, or stiffness" fulfilled and considered the joint having bony swelling, limited range of motion, and deformity, but not soft swelling or tenderness.

Comorbidities. Seventeen of the 18 self-reported assessed comorbidities were assessed by a modified Dutch version of the Charlson index (total score range 0–33; Table 2)³⁷. "Malignancy" was used instead of "any tumor, leukemia or lymphoma." When "connective tissue disease" was reported, the medical chart was verified to ascertain rheumatic disease other than hand OA. Osteoporosis was the 18th self-reported comorbidity, but was not weighted in the Charlson score. Obesity (BMI ≥ 30 kg/m²) was determined using physical examination.

The total number of comorbidities was summed (0–19), i.e., self-reported comorbidities and obesity. Presence of any comorbidity was defined as having at least 1 of these 19 comorbidities. To study specific types of comorbidities, some comorbidities were grouped: myocardial infarction, cardiac failure, peripheral vascular disease, and cerebrovascular disease (stroke) into CV disease; ulcer disease, mild and severe liver disease into gastrointestinal disease; malignancy and metastatic disease into malignant disease; diabetes mellitus with and without end-organ damage into diabetic disease.

Because knee and/or hip OA could be considered phenotypes of OA (i.e.,

Table 2. Prevalence of comorbidities and generalized osteoarthritis (OA) in a hand OA population (n = 538) in secondary care.

Any comorbidity*		
Any comorbidity present, n (%)	287	(54)
No. comorbidities per patient, 0–19, median (range)	1	(0–6)
Modified** Charlson index*	W	
Modified Charlson score per patient, 0–17, median (range)	0	(0–8)
Comorbidities in modified Charlson index, n (%)		
Myocardial infarction	1	14 (3)
Congestive heart failure	1	25 (5)
Peripheral vascular disease	1	20 (4)
Cerebrovascular accident	1	12 (2)
Dementia	1	2 (0)
Chronic pulmonary disease	1	58 (11)
Connective tissue disease	1	48 (9)
Ulcer disease	1	9 (2)
Liver disease, mild	1	14 (3)
Liver disease, severe	3	2 (0)
Diabetes mellitus	1	37 (7)
Diabetes mellitus, complicated	2	9 (2)
Hemiplegia	2	6 (1)
Renal disease	2	7 (1)
Malignancy	2	30 (6)
Malignancy, metastatic disease	6	4 (1)
HIV	6	0 (0)
Other comorbidities*		
Osteoporosis, self-reported, n (%)	42	(8)
Obesity: body mass index ≥ 30 kg/m ² , n (%)	121	(23)
Generalized OA*		
Knee and/or hip OA, no. patients (%)	161	(31)
Knee OA		
Fulfilling ACR criteria, 1 knee	59	(11)
Fulfilling ACR criteria, both knees	37	(7)
Prosthesis, 1 or both knees [^]	25	(5)
Hip OA		
Fulfilling ACR criteria, 1 hip	24	(5)
Fulfilling ACR criteria, both hips	12	(2)
Prosthesis, 1 or both hips [^]	22	(4)

* Any comorbidity: n = 531; self-reported comorbidity: n = 519; obesity: n = 523; knee OA/hip OA: 526. ** Modification: malignancy as combination option instead of any tumor, leukemia, or lymphoma. [^] Seven and 1 patients, respectively, had a prosthesis in 1 knee or hip and fulfilled ACR criteria on the other side; these patients are in the prosthesis groups. HIV: human immunodeficiency virus; ACR: American College of Rheumatology; W: assigned weight for diseases in Charlson score.

generalized OA), having knee/hip OA was not regarded as a comorbidity, but assessed separately.

In a subgroup (patients included after January 2011), the Hospital Anxiety and Depression Scale (HADS; range total scale 0–42) was assessed^{38,39}. A total HADS score ≥ 16 was used to define depression-anxiety as a comorbidity²².

Radiographs. Joints of both hands (n = 30) were scored 0–4 on conventional dorsal-volar radiographs, according to the Kellgren-Lawrence (KL)⁴⁰ grading scale. Osteophytes and joint space narrowing (JSN) were scored 0–3 (IP 0–1) following the Osteoarthritis Research Society International atlas (MCP scored as PIP)⁴¹. Erosive disease was defined as having ≥ 1 joint with an eroded or remodeled subchondral plate according to Verbruggen and Veys⁴². Radiographs were scored blinded for demographic and clinical data (WD). Intraobserver reliability, based on randomly selected radiographs

(10%), was good; intraclass correlation coefficient was > 0.9 for different scores. Arthroplasty/arthrodesis was considered endstage radiographic OA (maximum score).

Statistical analysis. Patient characteristics were compared using Student *t* tests, chi-squared tests, or Mann-Whitney *U* tests when appropriate. Multivariable linear regression analysis was used to study cross-sectional associations between presence of any comorbidity, Charlson index score, and specific comorbidities (determinants) and HRQOL, self-reported hand function and pain, and TJC (outcomes). Data were presented as regression coefficients (95% CI), reflecting mean score differences when comparing 2 groups (e.g., presence/absence of comorbidity; Table 3). Thereafter, we evaluated clinical relevance by studying associations between presence of any comorbidity or specific comorbidities (determinant) and function or pain above the reference curve cutoff (outcome). For this we used a Poisson regression model with long link function and robust standard errors and presented results as risk ratios (RR) with 95% CI⁴³. All analyses were adjusted for age and sex. Other variables were not known from theory to affect the association or did not act as a confounder in univariate analysis nor in stepwise regression and hence were not adjusted for. SPSS software for Windows, V.23.0 (IBM) was used.

RESULTS

Study population. According to the clinical hand OA diagnosis, 629 patients were eligible for inclusion, of whom 80 did not consent to participate and 11 fulfilled exclusion criteria after medical chart verification. The remaining 538 patients were included (Figure 1, Table 1). Data were complete for age, sex, and physical examination. Less than 3% of data was missing for other variables, except SF-36 (5%), symptom duration (7%), and nutraceutical use (4%). Patients with complete data for all variables in Table 1 did not differ from the total population (not shown).

Of the patients in our cohort, 90% (463/526, 12 patients missing data) fulfilled the ACR criteria for hand OA. They had a mean age of 61 years and the majority were women (463/538, 86%). One-fourth had a low education level

(141/524, 27%). Two-thirds used medication for joint pain (351/538, 67%; predominantly acetaminophen).

Physical HRQOL was lower in our population than in the general population ($p < 0.001$), whereas mental HRQOL was similar. No sex differences were observed in PCS or MCS (not shown). The mean observed disease-specific burden as measured with AUSCAN was 15.6 for function and 9.3 for pain (Table 1). Women reported worse function and more pain than men (not shown).

Many joints had bony swellings (median 11), while few joints had soft swelling (median 0; Table 1). Mean (SD) TJC was 4.8 (5.2).

Ninety-nine percent of patients had at least 1 joint with KL score above zero, 97% had at least 1 joint with osteophytes, and 90% at least 1 joint with JSN, while almost 30% showed radiographic erosive disease. Seven hand joints in 6 patients had arthroplasty or arthrodesis at baseline.

Table 2 depicts prevalence of comorbidities. Patients with complete data ($n = 511$) did not differ from the total population (not shown). Any comorbidity (i.e., self-reported and obesity) was present in 54% (287/531) of patients, while 43% (222/519) had self-reported comorbidity. Thirty-one percent (161/526) of patients had knee and/or hip OA. As shown in Table 3, obesity was the most prevalent comorbidity, followed by CV and pulmonary disease.

Association of comorbidity with disease burden. Presence of any comorbidity was associated with higher disease burden than when comorbidity was absent; adjusted mean score difference (95% CI) for HRQOL -4.4 (-5.8 to -3.0 ; MCID 2), hand function 1.9 (0.4–3.3; MCII 1.4), hand pain 1.4 (0.6–2.1; MCII 1.6), and hand TJC 1.3 (0.4–2.2). The number of comorbidities was associated with lower HRQOL and more hand complaints (Figure 2). Also, Charlson index score was associated; adjusted β (95% CI) for HRQOL -1.4

Table 3. Associations between specific types of comorbidities and physical health-related quality of life (HRQOL), self-reported hand function or hand pain and tender joint count in a hand osteoarthritis (OA) population in secondary care.

Variables	Present, n	Physical HRQOL MCID	Self-reported Function MCII	Self-reported Pain MCII	Tender Joint Count
Self-reported comorbidity [^]					
Cardiovascular disease**	59	-4.3 (-6.6 to -2.0)	1.7 (-0.7 to 4.1)	1.4 (0.2–2.7)	1.4 (-0.1 to 2.8)
Pulmonary disease	58	-4.8 (-7.1 to -2.6)	3.0 (0.7–5.3)	1.2 (0.01–2.4)	1.2 (-0.2 to 2.6)
Diabetes mellitus**	40	-2.2 (-5.0 to 0.5)	1.8 (-1.0 to 4.6)	1.2 (-0.2 to 2.7)	0.9 (-0.8 to 2.5)
Malignant disease**	33	0.3 (-2.7 to 3.2)	0.3 (-2.7 to 3.3)	1.2 (-0.4 to 2.7)	-0.1 (-1.9 to 1.8)
Gastrointestinal disease**	24	-2.1 (-5.5 to 1.2)	2.3 (-1.1 to 5.7)	0.9 (-0.9 to 2.7)	0.9 (-1.2 to 3.0)
Osteoporosis	42	-1.5 (-4.2 to 1.3)	3.6 (0.9–6.4)	1.1 (-0.3 to 2.5)	1.5 (-0.2 to 3.1)
Connective tissue disease	48	-4.3 (-6.7 to -1.8)	3.6 (1.1–6.1)	2.4 (1.1–3.7)	2.2 (0.7–3.7)
Physical examination–based comorbidity [^]					
Obesity	121	-4.1 (-5.7 to -2.4)	1.3 (-0.4 to 3.0)	0.8 (-0.1 to 1.7)	0.1 (-0.9 to 1.2)

Statistically significant data are in bold face. [^] All comorbidity: self-reported comorbidity; obesity: $n = 519$, 523. * Adjusted for age and sex. ** Cardiovascular disease: combination of myocardial infarction, cardiac failure, peripheral vascular disease, and stroke. Diabetes mellitus: combination of diabetes with and without end-organ damage. Malignant disease: combination of malignancy and metastatic solid tumor. Gastrointestinal disease: combination of ulcer disease and mild and moderate/severe liver disease. MCID: minimal clinically important difference; MCII: minimal clinically important improvement.




Figure 1. Flowchart for the HOSTAS study showing inclusion and completeness of data. HOSTAS: Hand OSTeoArthritis in Secondary care; OA: osteoarthritis.




Figure 2. Mean scores with (SD) of (A) health-related quality of life (HRQOL; range 0–100, mean 50), as assessed by Medical Outcomes Study Short Form-36 physical component scale and normalized to the Dutch population; (B) self-reported hand function (0–36) and (C) self-reported hand pain (0–20), both assessed by the Australian/Canadian hand osteoarthritis Index; and (D) tender joint count (0–30) assessed by physical examination of patients with 0, 1, 2, 3, or ≥ 4 comorbidities. For HRQOL, a lower score means worse health. For the other outcomes, a higher score means worse health. Only patients with complete data on all comorbidities are depicted (n = 511).

(−2.0 to −0.8), function 1.1 (0.5–1.7), pain 0.7 (0.4–1.0), and TJC 0.6 (0.2–0.9).

In Table 3 we show associations between specific types of comorbidities and disease burden, presented as mean differences between groups of presence/absence of the comorbidity. Self-reported connective tissue disease, but also pulmonary disease and CV disease, were associated with both general and hand-specific disease burden. Obesity was only associated with HRQOL, while osteoporosis was only associated with self-reported function. Diabetes, malignant disease, and gastrointestinal disease were not associated with HRQOL or hand complaints.

Knee/hip OA was associated with both general and disease-specific burden [adjusted mean difference (95% CI): HRQOL −3.7 (−5.2 to −2.1), function 1.8 (0.2 to 3.4), pain 0.8 (−0.03 to 1.6), and TJC 1.7 (0.8 to 2.6).

Additional analyses in 381 patients with HADS data (same characteristics as total population) showed that depression-anxiety ($n = 50$, 13%) was associated with higher disease-specific burden; adjusted mean difference (95% CI) for HRQOL −2.2 (−4.7 to 0.2), function 4.4 (2.1–6.8), pain 2.2 (1.0–3.5), and TJC 2.5 (1.1–4.0). In this subgroup, the presence of any comorbidity (60% of patients when including depression-anxiety) and number of comorbidities were associated with high disease burden (data not shown).

Clinical relevance. The mean score difference in HRQOL and hand function in the presence of any comorbidity was higher than the MCII/MCID, but this was not found for self-reported hand pain. For the specific types of comorbidities, most mean differences in Table 3 that were statistically significant (bold) were also higher than the MCII/MCID, except for self-reported pain in patients with pulmonary and CV disease.

Poisson regression confirmed the clinically relevant role of presence and number of comorbidities: adjusted RR (95% CI) for hand function or pain above the age- and sex-specific cutoff for presence of any comorbidity was 1.2 (1.01–1.5) and 1.2 (1.02–1.5), and per additional comorbidity 1.2 (1.1–1.2) and 1.2 (1.1–1.2), respectively. For example, this means that patients with any comorbidity present have a 20% greater chance to have an AUSCAN function score in the highest 5% of their age and sex category than patients without any comorbidity. For the specific types of comorbidities, all mean differences in Table 3 that were statistically significant (bold) were associated in this analysis, except for the association between pulmonary disease and pain. For example, RR (95% CI) for function or pain above the cutoff for presence of connective tissue disease were 1.6 (1.2–2.0) and 1.6 (1.3–2.0), respectively; other data not shown.

DISCUSSION

In our large cohort of patients with primary hand OA from a rheumatology outpatient clinic, we studied the relationship between comorbidities and general and hand-specific disease

burden and evaluated its relevance. We showed that comorbidity was associated with higher disease burden, both for musculoskeletal comorbidities such as connective tissue disease, as well as for nonmusculoskeletal comorbidities including pulmonary or CV disease and depression-anxiety. When compared to an MCII/MCID and to population-based reference values, we observed that the difference was higher. To our knowledge, this is the first report that describes such relations in a quantitative way.

Comorbidities were prevalent in our study: more than half had any comorbidity, while 40% had a comorbidity included in the Charlson index. Patients with knee OA in the Osteoarthritis Initiative, which also used this index, reported fewer comorbidities (28%). However, their study included fewer women and another OA type, which could explain the difference¹⁸.

The number of comorbidities was associated with higher disease burden. Contrary to our findings, a study in patients with thumb base (osteo)arthritis reported no association between number of comorbidities and worse function²⁴. However, it is unclear whether that study used a validated comorbidity index and a different subset of hand OA was studied. In another cohort, presence of 3 or more comorbidities did not affect the association between hand OA and hand disability¹². However, participants in this population-based study were older than in our study. Moreover, this study did not focus on hand OA patients and could, therefore, not be generalized to hand OA patients in primary or secondary care.

Our hand OA study is one of the first to report prevalence of separate comorbid conditions. We found that nonmusculoskeletal comorbidities such as pulmonary and CV disease were associated with disease burden. This is in accordance with studies in patients with several OA types that also report a role for nonmusculoskeletal comorbidities, such as diabetes, chronic pulmonary disease, and cardiac disease^{17,20,21}. Because numerous papers in literature report on the unfavorable effect of multimorbidity on quality of life^{8,10,44}, it seems difficult to attribute disease burden to 1 condition. To study the separate roles of concurrent conditions, one can analyze interaction in a population-based study, as was done for knee OA and obesity⁴⁵ and for hand OA and several diseases¹².

A strength of our study is the large number of well-described patients, including primary hand OA in different disease stages and subsets. This is illustrated in our data; this cohort includes patients with zero tender joints or without radiographic hand OA but also with 29/30 tender joints or erosive disease. Nevertheless, this population is patients with primary hand OA recruited from our rheumatology outpatient clinic in a secondary and tertiary referral center. Therefore, it should be acknowledged that this population could be different from a primary care population and that results should be extrapolated with caution. Another strength of our study is that we compared the values to the

MCII/MCID and to age- and sex-specific reference values. Because age and sex are modifiers of clinical outcomes in hand OA, this adds to the validity of our results.

Not only from a clinical but also from a methodological perspective, comorbidity is of importance. Comorbidity could be a contextual factor, i.e., a factor that might influence (interpretation of) results, and was identified that way by the Outcome Measures in Rheumatology hand OA working group^{26,27}. Our results confirm that comorbidity is a contextual factor to consider when interpreting core outcomes such as HRQOL, hand function, and hand pain, especially when the effect size of the studied intervention is small. If any recommendations could be given based on our study, perhaps the most important is to consider adjustment for the number of comorbidities or for presence of any comorbidity. Depending on the research question, adjustment for specific types of comorbidities could also be considered.

There are some limitations we need to address. First, because of our cross-sectional design, we were unable to draw any conclusions about the effect of comorbidity, or its treatment, on hand OA disease burden over time. Several papers indicate that multimorbidity could be related to undertreatment of hand OA, especially when seemingly unrelated conditions are present^{46,47}. Therefore, we expect that adequate management of all morbidity of a patient would reduce disease burden over time. Future research could build upon our current study, e.g., by studying exercise and/or medication use to reduce comorbidity. Second, we only assessed psychiatric diseases in a subgroup and defined depression-anxiety by HADS score, which is not a diagnostic tool. However, HADS has shown to be a valid instrument to detect mood disorders in patients with OA²². Third, most comorbidities were self-reported. However, diagnostic accuracy of self-reported disease seems acceptable⁴⁸, the Charlson is a validated index⁴⁹, and prevalence of comorbidity in our population was mostly similar to another small hand OA population⁵⁰. Therefore, we think the self-report is sufficiently reliable to reflect comorbidity burden in our population. Fourth, we assessed the MCID for HRQOL with a value derived from a study in lower extremity OA³⁰. However, because no hand OA studies were available, we found this the best option.

In our large primary hand OA cohort, presence and number of comorbidities as well as separate comorbid conditions showed an association with both general and disease-specific burden that is larger than the MCID/MCII. We conclude that comorbidities have a role in the assessment of hand OA outcomes and may be considered as contextual factors as well as in clinical practice. To optimize disease management, a holistic view, taking all concurrent conditions of a patient into account, seems relevant. Future studies can analyze the longitudinal relationship between comorbidities and hand OA disease burden and can assess the effect of interventions.

ACKNOWLEDGMENT

We thank the patients of the HOSTAS cohort for participation in this study and research nurses B. van Schie-Geyer, A. Wongsodihardjo, and M. Janson, and data managers J. van Krol-Berkel and C. Kromme in the Rheumatology Department of the LUMC, and technicians in the Radiology Department of the LUMC for support in data collection.

REFERENCES

1. Kloppenburg M, Kwok WY. Hand osteoarthritis—a heterogeneous disorder. *Nat Rev Rheumatol* 2012;8:22-31.
2. Liu R, Damman W, Kaptein AA, Rosendaal FR, Kloppenburg M. Coping styles and disability in patients with hand osteoarthritis. *Rheumatology* 2016;55:411-8.
3. Kortekaas MC, Kwok WY, Reijnen M, Watt I, Huizinga TW, Kloppenburg M. Pain in hand osteoarthritis is associated with inflammation: the value of ultrasound. *Ann Rheum Dis* 2010;69:1367-9.
4. Kwok WY, Kloppenburg M, Rosendaal FR, van Meurs JB, Hofman A, Bierma-Zeinstra SM. Erosive hand osteoarthritis: its prevalence and clinical impact in the general population and symptomatic hand osteoarthritis. *Ann Rheum Dis* 2011;70:1238-42.
5. Bijsterbosch J, Scharloo M, Visser AW, Watt I, Meulenbelt I, Huizinga TW, et al. Illness perceptions in patients with osteoarthritis: change over time and association with disability. *Arthritis Care Res* 2009;61:1054-61.
6. Radner H, Smolen JS, Aletaha D. Impact of comorbidity on physical function in patients with rheumatoid arthritis. *Ann Rheum Dis* 2010;69:536-41.
7. Baillet A, Gossec L, Carmona L, Wit MD, van Eijk-Hustings Y, Bertheussen H, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. *Ann Rheum Dis* 2016;75:965-73.
8. Williams JS, Egede LE. The association between multimorbidity and quality of life, health status and functional disability. *Am J Med Sci* 2016;352:45-52.
9. Kruijshaar ME, Hoeymans N, Bijl RV, Spijker J, Essink-Bot ML. Levels of disability in major depression: findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). *J Affect Disord* 2003;77:53-64.
10. Fortin M, Lapointe L, Hudon C, Vanasse A, Ntutu AL, Maltais D. Multimorbidity and quality of life in primary care: a systematic review. *Health Qual Life Outcomes* 2004;2:51.
11. Ryan A, Wallace E, O'Hara P, Smith SM. Multimorbidity and functional decline in community-dwelling adults: a systematic review. *Health Qual Life Outcomes* 2015;13:168.
12. Siviero P, Zambon S, Limongi F, Castell MV, Cooper C, Deeg DJ, et al. How hand osteoarthritis, comorbidity and pain interact to determine functional limitation in older people: observations from the European Project on Osteoarthritis study. *Arthritis Rheumatol* 2016;68:2662-70.
13. Slatkowsky-Christensen B, Mowinckel P, Loge JH, Kvien TK. Health-related quality of life in women with symptomatic hand osteoarthritis: A comparison with rheumatoid arthritis patients, healthy controls, and normative data. *Arthritis Care Res* 2007;57:1404-9.
14. Nieves-Plaza M, Castro-Santana LE, Font YM, Mayor AM, Vilá LM. Association of hand or knee osteoarthritis with diabetes mellitus in a population of Hispanics from Puerto Rico. *J Clin Rheumatol* 2013;19:1-6.
15. Haugen IK, Ramachandran VS, Misra D, Neogi T, Niu J, Yang T, et al. Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham Heart Study. *Ann Rheum Dis* 2015;74:74-81.

16. Visser AW, Ioan-Facsinay A, de Mutsert R, Widya RL, Loef M, de Roos A, et al. Adiposity and hand osteoarthritis: the Netherlands Epidemiology of Obesity study. *Arthritis Res Ther* 2014;16:R19.
17. Caporali R, Cimmino MA, Sarzi-Puttini P, Scarpa R, Parazzini F, Zaninelli A, et al. Comorbid conditions in the AMICA study patients: effects on the quality of life and drug prescriptions by general practitioners and specialists. *Semin Arthritis Rheum* 2005;35:31-7.
18. Collins JE, Katz JN, Dervan EE, Losina E. Trajectories and risk profiles of pain in persons with radiographic, symptomatic knee osteoarthritis: data from the osteoarthritis initiative. *Osteoarthritis Cartilage* 2014;22:622-30.
19. Hawker GA, Gignac MA, Badley E, Davis AM, French MR, Li Y, et al. A longitudinal study to explain the pain-depression link in older adults with osteoarthritis. *Arthritis Care Res* 2011;63:1382-90.
20. Reeuwijk KG, de Rooij M, van Dijk GM, Veenhof C, Steultjens MP, Dekker J. Osteoarthritis of the hip or knee: which coexisting disorders are disabling? *Clin Rheumatol* 2010;29:739-47.
21. Wesseling J, Welsing PM, Bierma-Zeinstra SM, Dekker J, Gorter KJ, Kloppenburg M, et al. Impact of self-reported comorbidity on physical and mental health status in early symptomatic osteoarthritis: the CHECK (Cohort Hip and Cohort Knee) study. *Rheumatology* 2013;52:180-8.
22. Axford J, Butt A, Heron C, Hammond J, Morgan J, Alavi A, et al. Prevalence of anxiety and depression in osteoarthritis: use of the Hospital Anxiety and Depression Scale as a screening tool. *Clin Rheumatol* 2010;29:1277-83.
23. Kwok WY, Vliet Vlieland TP, Rosendaal FR, Huizinga TW, Kloppenburg M. Limitations in daily activities are the major determinant of reduced health-related quality of life in patients with hand osteoarthritis. *Ann Rheum Dis* 2011;70:334-6.
24. Calfee R, Chu J, Sorensen A, Martens E, Elfar J. What is the impact of comorbidities on self-rated hand function in patients with symptomatic trapeziometacarpal arthritis? *Clin Orthop Relat Res* 2015;473:3477-83.
25. Magnusson K, Hagen KB, Østerås N, Nordsletten L, Natvig B, Haugen IK. Diabetes is associated with increased hand pain in erosive hand osteoarthritis: data from a population-based study. *Arthritis Care Res* 2015;67:187-95.
26. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino MA, et al. Developing core outcome measurement sets for clinical trials: OMERACT Filter 2.0. *J Clin Epidemiol* 2014;67:745-53.
27. Kloppenburg M, Bøyesen P, Visser AW, Haugen IK, Boers M, Boonen A, et al. Report from the OMERACT Hand Osteoarthritis Working Group: set of core domains and preliminary set of instruments for use in clinical trials and observational studies. *J Rheumatol* 2015;42:2190-7.
28. van der Zee K, Sanderman R. [Measuring general health with the RAND-36, a manual. 2nd ed]. [Manual in Dutch] Groningen: University of Groningen, Northern Center for Health Issues; 2012.
29. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. *J Clin Epidemiol* 1998;51:1055-68.
30. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. *Arthritis Care Res* 2001;45:384-91.
31. Bellamy N, Campbell J, Haraoui B, Buchbinder R, Hobby K, Roth JH, et al. Dimensionality and clinical importance of pain and disability in hand osteoarthritis: development of the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index. *Osteoarthritis Cartilage* 2002;10:855-62.
32. Bellamy N, Hochberg M, Tubach F, Martin-Mola E, Awada H, Bombardier C, et al. Development of multinational definitions of minimal clinically important improvement and patient acceptable symptomatic state in osteoarthritis. *Arthritis Care Res* 2015; 67:972-80.
33. Kroon FPB, Ramiro S, Royston P, Le Cessie S, Rosendaal FR, Kloppenburg M. Reference curves for the Australian/Canadian Hand Osteoarthritis Index in the middle-aged Dutch population. *Rheumatology* 2017;56:745-52.
34. Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. *Arthritis Rheum* 1990;33:1601-10.
35. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. *Arthritis Rheum* 1986;29:1039-49.
36. Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. *Arthritis Rheum* 1991;34:505-14.
37. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373-83.
38. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* 1983;67:361-70.
39. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. *Psychol Med* 1997;27:363-70.
40. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthritis. *Ann Rheum Dis* 1957;16:494-502.
41. Altman RD, Gold GE. Atlas of individual radiographic features in osteoarthritis, revised. *Osteoarthritis Cartilage* 2007;15 Suppl 1: A1-56.
42. Verbruggen G, Veys EM. Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger joints. *Arthritis Rheum* 1996;39:308-20.
43. Knol MJ, Le Cessie S, Algra A, Vandenbroucke JP, Groenwold RH. Overestimation of risk ratios by odds ratios in trials and cohort studies: alternatives to logistic regression. *CMAJ* 2012;184:895-9.
44. Sprangers MA, de Regt EB, Andries F, van Agt HM, Bijl RV, de Boer JB, et al. Which chronic conditions are associated with better or poorer quality of life? *J Clin Epidemiol* 2000;53:895-907.
45. Visser AW, de Mutsert R, Bloem JL, Reijnierse M, Kazato H, le Cessie S, et al. Do knee osteoarthritis and fat-free mass interact in their impact on health-related quality of life in men? Results from a population-based cohort. *Arthritis Care Res* 2015;67:981-8.
46. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. *N Engl J Med* 1998;338:1516-20.
47. Cheraghi-Sohi S, Bower P, Kennedy A, Morden A, Rogers A, Richardson J, et al. Patient priorities in osteoarthritis and comorbid conditions: a secondary analysis of qualitative data. *Arthritis Care Res* 2013;65:920-7.
48. Kriegsman DM, Penninx BW, van Eijk JT, Boeke AJ, Deeg DJ. Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients' self-reports and on determinants of inaccuracy. *J Clin Epidemiol* 1996;49:1407-17.
49. Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by questionnaire rather than medical record review? *Med Care* 1996;34:73-84.
50. Haugen IK, Slatkowsky Christensen B, Bøyesen P, Sesseng S, van der Heijde D, Kvien TK. Increasing synovitis and bone marrow lesions are associated with incident joint tenderness in hand osteoarthritis. *Ann Rheum Dis* 2016;75:702-8.

Correction

Do Comorbidities Play a Role in Hand Osteoarthritis Disease Burden? Data from the Hand Osteoarthritis in Secondary Care Cohort

Damman W, Liu R, Kroon FP, Reijnders M, Huizinga TW, Rosendaal FR, Kloppenburg M. Do comorbidities play a role in hand osteoarthritis disease burden? Data from the Hand Osteoarthritis in Secondary Care Cohort. *J Rheumatol* 2017; doi:10.3899/jrheum.170208. The classification of knee osteoarthritis (OA), according to the American College of Rheumatology criteria, was incorrectly reported in this article. As a result, the numbers in Table 2 for “generalized OA” and “knee OA,” and the estimates for the association of generalized OA and disease burden, are incorrect. The corrected version of the affected part of Table 2 is given below.

In addition, some portions of the text are incorrect. The corrected versions:

In the Results section, page 1662, column 2, fifth paragraph: “Forty-three percent (227/526) of patients had knee and/or hip OA.”

In the Results section, page 1664, column 1, third paragraph: “Knee/hip OA was associated with both general and disease-specific burden [adjusted mean difference (95% CI)]: HRQOL -4.2 (-5.6 to -2.8), function 1.3 (-0.2 to 2.7), pain 0.7 (-0.1 to 1.5), and TJC 1.1 (0.2–2.0).”

The incorrect numbers and estimates do not affect the article’s message, other results, or discussion.

doi:10.3899/jrheum.170208.C1

Corrected Table 2. Prevalence of generalized osteoarthritis (OA) in a hand OA population (n = 538) in secondary care.

Generalized OA

Knee and/or hip OA, no. patients (%)	227	(43)
Knee OA		
Fulfilling ACR criteria, 1 knee	89	(17)
Fulfilling ACR criteria, both knees	83	(16)
Prosthesis, 1 or both knees [^]	25	(5)
Hip OA		
Fulfilling ACR criteria, 1 hip	24	(5)
Fulfilling ACR criteria, both hips	12	(2)
Prosthesis, 1 or both hips [^]	22	(4)

[^] Nine patients and 1 patient, respectively, had a prosthesis in 1 knee or hip and fulfilled ACR criteria on the other side; these patients are in the prosthesis groups. ACR: American College of Rheumatology.